MCID: PNC015
MIFTS: 27

Pancreatic Acinar Cell Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Acinar Cell Adenocarcinoma

MalaCards integrated aliases for Pancreatic Acinar Cell Adenocarcinoma:

Name: Pancreatic Acinar Cell Adenocarcinoma 12 14
Acinar Cell Adenocarcinoma of the Pancreas 69
Pancreatic Acinar Cell Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5742
NCIt 47 C7977
UMLS 69 C0279661

Summaries for Pancreatic Acinar Cell Adenocarcinoma

Disease Ontology : 12 A pancreatic adenocarcinoma that has material basis in cells with morphological resemblance to acinar cells and is associated with increased serum lipase.

MalaCards based summary : Pancreatic Acinar Cell Adenocarcinoma, also known as acinar cell adenocarcinoma of the pancreas, is related to acinar cell carcinoma of pancreas and acinar cell carcinoma, and has symptoms including abdominal pain, icterus and pruritus. An important gene associated with Pancreatic Acinar Cell Adenocarcinoma is BCL10 (B-Cell CLL/Lymphoma 10). The drugs Fluorouracil and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include pancreas, lung and liver, and related phenotype is Decreased shRNA abundance (Z-score < -2).

Related Diseases for Pancreatic Acinar Cell Adenocarcinoma

Graphical network of the top 20 diseases related to Pancreatic Acinar Cell Adenocarcinoma:



Diseases related to Pancreatic Acinar Cell Adenocarcinoma

Symptoms & Phenotypes for Pancreatic Acinar Cell Adenocarcinoma

UMLS symptoms related to Pancreatic Acinar Cell Adenocarcinoma:


abdominal pain, icterus, pruritus

GenomeRNAi Phenotypes related to Pancreatic Acinar Cell Adenocarcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 9.28 CELA1 AFP
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 9.28 CELA1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.28 CELA1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-48 9.28 AFP
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 9.28 AFP
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.28 CELA1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 9.28 AFP
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.28 AFP

Drugs & Therapeutics for Pancreatic Acinar Cell Adenocarcinoma

Drugs for Pancreatic Acinar Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 84)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
2
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
3
Levoleucovorin Approved Phase 3,Phase 2,Phase 1 68538-85-2
4
Pancrelipase Approved Phase 3,Phase 2,Phase 1 53608-75-6
5
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
6
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
7
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
8 Antidotes Phase 3,Phase 2,Phase 1
9 Anti-Infective Agents Phase 3,Phase 2,Phase 1
10 Antimetabolites Phase 3,Phase 2,Phase 1
11 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
12 Antiviral Agents Phase 3,Phase 2,Phase 1
13 Calcium, Dietary Phase 3,Phase 2,Phase 1
14 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
15 Micronutrients Phase 3,Phase 2,Phase 1
16 pancreatin Phase 3,Phase 2,Phase 1
17 Protective Agents Phase 3,Phase 2,Phase 1
18 Trace Elements Phase 3,Phase 2,Phase 1
19 Vitamin B Complex Phase 3,Phase 2,Phase 1
20 Vitamins Phase 3,Phase 2,Phase 1
21 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
22
Erlotinib Hydrochloride Phase 3,Phase 1 183319-69-9 176871
23 Folate Nutraceutical Phase 3,Phase 2,Phase 1
24 Vitamin B9 Nutraceutical Phase 3,Phase 2,Phase 1
25
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
26
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
27
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
28
Oxaliplatin Approved, Investigational Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
29
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
30
Metformin Approved Phase 2,Early Phase 1 657-24-9 14219 4091
31
Irinotecan Approved, Investigational Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
32
nivolumab Approved Phase 2 946414-94-4
33
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
34
Ifosfamide Approved Phase 2 3778-73-2 3690
35
Mechlorethamine Approved Phase 2 51-75-2 4033
36 Bryostatin 1 Investigational Phase 2 83314-01-6
37
Camptothecin Experimental Phase 2,Phase 1 7689-03-4
38 Angiogenesis Inhibitors Phase 2
39 Angiogenesis Modulating Agents Phase 2
40 Gastrointestinal Agents Phase 2,Phase 1
41 Adjuvants, Immunologic Phase 2
42 Albumin-Bound Paclitaxel Phase 2,Phase 1
43 Antimitotic Agents Phase 2,Phase 1
44 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
45 Anti-Bacterial Agents Phase 2,Phase 1
46 Antibiotics, Antitubercular Phase 2,Phase 1
47 Hypoglycemic Agents Phase 2,Early Phase 1
48 topoisomerase I inhibitors Phase 2,Phase 1
49 Topoisomerase Inhibitors Phase 2,Phase 1
50 Antibodies Phase 2

Interventional clinical trials:

(show all 30)

id Name Status NCT ID Phase Drugs
1 Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer Completed NCT00058201 Phase 3 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
2 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery Recruiting NCT01013649 Phase 3 Capecitabine;Chemotherapy;Erlotinib Hydrochloride;Fluorouracil;Gemcitabine Hydrochloride
3 Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer Completed NCT00416793 Phase 2 bortezomib;carboplatin
4 Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine Completed NCT00397787 Phase 2 sunitinib malate
5 Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy Completed NCT01658943 Phase 2 Akt Inhibitor MK2206;Fluorouracil;Oxaliplatin;Selumetinib
6 Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas Completed NCT00085371 Phase 2 triapine
7 Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer Completed NCT00031694 Phase 2 paclitaxel;bryostatin 1
8 Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer Recruiting NCT01666730 Phase 2 metformin hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
9 Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer Recruiting NCT02047474 Phase 2 oxaliplatin;leucovorin calcium;irinotecan hydrochloride;fluorouracil
10 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
11 Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Active, not recruiting NCT01280058 Phase 2 Carboplatin;Paclitaxel
12 Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery Active, not recruiting NCT01234935 Phase 2 dasatinib;gemcitabine hydrochloride
13 Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer Suspended NCT02178436 Phase 1, Phase 2 gemcitabine hydrochloride;paclitaxel albumin-stabilized nanoparticle formulation;selinexor
14 Mitomycin C and Ifosfamide in Treating Patients With Metastatic Pancreatic Cancer Terminated NCT00967291 Phase 2 ifosfamide;mitomycin C
15 CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Completed NCT01839981 Phase 1 6,8-bis(benzylthio)octanoic acid
16 Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride Completed NCT00981162 Phase 1 sorafenib tosylate;everolimus
17 ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery Recruiting NCT01825603 Phase 1 ADH-1;cisplatin;gemcitabine hydrochloride
18 Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer Active, not recruiting NCT01770132 Phase 1 porfimer sodium;gemcitabine hydrochloride
19 Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery Active, not recruiting NCT00669734 Phase 1
20 CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer Active, not recruiting NCT01835041 Phase 1 6,8-bis(benzylthio)octanoic acid;oxaliplatin;leucovorin calcium;irinotecan hydrochloride;fluorouracil
21 Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery Active, not recruiting NCT01739439 Phase 1 gemcitabine hydrochloride
22 GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery Active, not recruiting NCT00878163 Phase 1 Erlotinib Hydrochloride;Gemcitabine Hydrochloride;Vismodegib
23 Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer Active, not recruiting NCT01924260 Phase 1 alisertib;gemcitabine
24 Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies Active, not recruiting NCT01643499 Phase 1 oxaliplatin;irinotecan hydrochloride;leucovorin calcium;fluorouracil
25 Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery Suspended NCT01537107 Phase 1 vismodegib;sirolimus
26 Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung Withdrawn NCT01741597 Phase 1
27 Stereotactic Radiosurgery and Metformin Hydrochloride in Treating Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer Recruiting NCT02153450 Early Phase 1 metformin hydrochloride
28 High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery Recruiting NCT02757859
29 Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer Active, not recruiting NCT01821612 oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;gemcitabine
30 Surgery for Pancreatic Tumors and Collection of Tumor Tissue for Study Terminated NCT00100321

Search NIH Clinical Center for Pancreatic Acinar Cell Adenocarcinoma

Genetic Tests for Pancreatic Acinar Cell Adenocarcinoma

Anatomical Context for Pancreatic Acinar Cell Adenocarcinoma

MalaCards organs/tissues related to Pancreatic Acinar Cell Adenocarcinoma:

39
Pancreas, Lung, Liver

Publications for Pancreatic Acinar Cell Adenocarcinoma

Variations for Pancreatic Acinar Cell Adenocarcinoma

Expression for Pancreatic Acinar Cell Adenocarcinoma

Search GEO for disease gene expression data for Pancreatic Acinar Cell Adenocarcinoma.

Pathways for Pancreatic Acinar Cell Adenocarcinoma

GO Terms for Pancreatic Acinar Cell Adenocarcinoma

Cellular components related to Pancreatic Acinar Cell Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.35 AFP CEL CELA1 CHGA SPINK1
2 extracellular space GO:0005615 9.02 AFP CEL CELA1 CHGA SPINK1

Sources for Pancreatic Acinar Cell Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....